Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy

Prostate

Volumn 75, Issue 1, 2015, Pages 103-111

  Seisen, Thomas ^a,b   Rouprêt, Morgan ^a,b   Brault, Didier ^b,c   Léon, Priscilla ^a,b   Cancel Tassin, Géraldine ^b,d   Compérat, Eva ^c   Renard Penna, Raphaele ^c   Mozer, Pierre ^a   Guechot, Jérome ^c   Cussenot, Olivier ^a,b,c,d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d HÔPITAL TENON   (France)

Author keywords

Antigens; Biological markers; Biopsy; Early detection of cancer; Prostate specific antigen; Prostatic neoplasm

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; BIOLOGICAL MARKER; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER SCREENING; COMPARATIVE EFFECTIVENESS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; IMAGE GUIDED BIOPSY; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; URINARY PROSTATE CANCER ANTIGEN 3 SCORE; VERY ELDERLY; AREA UNDER THE CURVE; BIOPSY; COHORT ANALYSIS; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; URINE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; AREA UNDER CURVE; BIOLOGICAL MARKERS; BIOPSY; COHORT STUDIES; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84918798172     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22898     Document Type: Article

References (27)

1. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Haggman M, Andersson SO, Bratell S, Spangberg A, Palmgren J, Steineck G, Adami HO, Johansson JE, SPCG-4 Investigators. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364: 1708-1717.
2. Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Paez A, Maattanen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, HakamaM, Moss SM, de Koning HJ, Auvinen A, ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-990.
3. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, CLapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorock PC, PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality results after 13 years of follow-up. J Natl Cancer Inst 2012; 104: 125-132.
4. Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, Kwiatkowski M, Recker F, Roobol MJ. Screening for prostate cancer decreases the risk of developing metastatic disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2012; 62: 745-752.
5. Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ, Efros M, Bidair M, Ward JF. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: A prospective multicenter clinical study. J Urol 2013; 190: 64-69.
6. Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, Scattoni V, Bini V, Freschi M, Sussman A, Ghaleh B, Le Corvoisier P, Alberola Bou J, Esquena Fernandez S, Graefen M, Guazzoni G. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: A multicentric European study. Eur Urol 2013; 63: 986-994.
7. Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, Dorigatti F, Ceriotti F, Pontillo M, Bini V, Freschi M, Montorsi F, Rigatti P. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: Results of a prospective study in a clinical setting. Eur Urol 2011; 60: 214-222.
8. Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem 2013; 59: 306-314.
9. Guazzoni G, Lazzeri M, Nava L, Lughezzani G, Larcher A, Scattoni V, Guadda GM, Bini V, Cestari A, Buffi NM, Freschi M, Rigatti P, Montorsi F. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012; 61: 455-466.
10. Ferro M, Bruzzese D, Perdonà S, Mazzarella C, Marino A, Sorrentino A, Di Carlo A, Autorino R, Di Lorenzo G, Buonerba C, Altieri V, Mariano A, Macchia V, Terracciano D. Predicting prostate biopsy outcome: Prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim Acta Int J Clin Chem 2012; 413: 1274-1278.
11. Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, Hu X, Meyer HA, Bogemann M, Miller K, Friedersdorff F. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2: ERG gene fusion with the serum [-2]proprostatespecific antigen-based prostate health index for detection of prostate cancer. Clin Chem 2013; 59: 280-288.
12. Perdonà S, Bruzzese D, Ferro M, Autorino R, Marino A, Mazzarella C, Perruolo G, Longo M, Spinelli R, Di Lorenzo G, Oliva A, De Sio M, Damiano R, Altieri V, Terracciano D. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 2013; 73: 227-235.
13. Scattoni V, Lazzeri M, Lughezzani G, De Luca S, Passera R, Bollito E, Randone D, Abdollah F, Capitanio U, Larcher A, Lista G, Gadda GM, Bini V, Montorsi F, Guazzoni G. Head-tohead comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J Urol 2013; 190: 496-501.
14. Ferro M, Bruzzese D, Perdonà S, Marino A, Mazzarella C, Perruolo G, D'Esposito V, Cosimato V, Buonerba C, Di Lorenzo G, Musi G, De Cobelli O, Chun FK, Terracciano D. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PloS ONE 2013; 8: e67687.
15. Semjonow A, Köpke T, Eltze E, Pepping-Schefers B, Bürgel H, Darte C. Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem 2010; 43: 926-928.
16. Groskopf J, Aubin SMJ, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS, Rittenhouse H. APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52: 1089-1095.
17. Epstein JI, Allsbrook WC, Jr., Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-1242.
18. Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm M-O, Bjartell AS, Montorsi F, Freedland SJ, Erbersdobler A, van der Kwast TH. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 2011; 60: 291-303.
19. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988; 44: 837-845.
20. Jansen FH, van Schaik RHN, Kurstjens J, HorningerW, Klocker H, Bektic J, Wildhagen MF, Roobol MJ, Bangma CH, Bartsch G. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010; 57: 921-927.
21. Leyten GHJM, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014; 65: 534-542.
22. Chevli KK, Duff M, Walter P, Yu C, Capuder B, Elshafei A, Malczewski S, KattanMW, Jones JS. Urinary PCA3 as a predictor of prostate cancer in a cohort of 3, 073 men undergoing initial prostate biopsy. J Urol. In press. doi: 10.1016/j.juro.2013.12.005.
23. Auprich M, Chun FK-H, Ward JF, Pummer K, Babaian R, Augustin H, Luger F, Gutschi S, Budaus L, Fish M, Huland H, Graefen M, Haese A. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 2011; 59: 96-105.
24. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, va Schaik RH, Mizrahi IA. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011; 185: 1650-1655.
25. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Horninger W, Klocker H, Mikolajczyk SD. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2-4 ng/ml prostate specific antigen. J Urol 2004; 171: 2239-2244.
26. Lughezzani G, Lazzeri M, Larcher A, Lista G, Scattoni V, Cestari A, Buffi NM, Bini V, Guazzoni G. Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy. J Urol 2012; 188: 1144-1150.
27. Hoeks CMA, Somford DM, van Oort IM, Vergunst H, Oddens JR, Smits GA, Roobol MJ, Bul M, Hambrock T, Witjes JA, Futterer JJ, Hulsbergen-van de Kaa CA, Barentsz JO. Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: A prospective multicenter cohort study. Invest Radiol 2014; 49: 165-172.